Everything below concerns thymosin beta-4. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
Helen Mary Heffernan is a New Zealand microbiologist, specialising in antibiotic resistance. In 2020, she was appointed a Companion of the New Zealand Order of Merit, for services to health. The Institute of Environmental Science and Research awarded Heffernan their Lifetime Achievement Award in 2018.
===== SeV suppression of regulatory T cells ===== Experiments with animal models have shown that, even after UV inactivation, SeV can block T-cell-mediated regulatory immunosuppression in tumors. The blocking mechanism is associated with the stimulation of SeV inactivated virions of interleukin 6 (IL-6) secretion by mature DCs. These effects lead to the eradication of most model tumors and inhibit the growth of the rest. It has been shown that F protein alone can trigger IL-6 production in DC in a fusion-independent manner.
== History == August Troendle founded Medpace in Cincinnati, Ohio, in 1992 as Medical Research Services. Troendle first became interested in the CRO sector after working in both the regulatory and pharmaceutical area. He began his career as a reviewer with the FDA, specializing in the development of lipid lowering therapies to treat high cholesterol. With a team of industry physicians, Jonathan Issacsohn and Evan Stein completed many early studies while at Medpace and Medpace Reference Laboratories on the use of statin therapies for the treatment of hypercholesterolemia. Another Medpace physician, David Orloff was regarded as an industry opinion leader in the study of metabolic diseases – most specifically diabetes and obesity. Troendle was honored for his work as a Medpace founder in 2012 by the Cincinnati Chamber of Commerce. Medpace completed construction on a new campus in 2012 in Madisonville, a neighborhood on the eastern side of Cincinnati. The project encompassed revitalizing an urban brownfield site formerly occupied by NuTone, and creating a state of the art LEED (Leadership in Energy and Environmental Design) certified campus. In 2022, Medpace announced a $150 million capital investment to expand its headquarters in Cincinnati, Ohio, adding an estimated expansion of 1,500 new jobs. Medpace expanded internationally through several acquisitions between 2007 and 2012. It acquired the Czech Republic contract research organization Monax in 2007, followed by Switzerland-based PharmaBrains AG in 2009.
Sources: en.wikipedia.org
Hemoglobin concentration measurement is among the most commonly performed blood tests, usually as part of a complete blood count. For example, it is typically tested before or after blood donation. Results are reported in g/L, g/dL or mol/L. 1 g/dL equals about 0.6206 mmol/L, although the latter units are not used as often due to uncertainty regarding the polymeric state of the molecule. This conversion factor, using the single globin unit molecular weight of 16,000 Da, is more common for hemoglobin concentration in blood. For MCHC (mean corpuscular hemoglobin concentration) the conversion factor 0.155, which uses the tetramer weight of 64,500 Da, is more common. Normal levels are:
There is a choroid plexus in each of the four ventricles. In the lateral ventricles, it is found in the body, and continued in an enlarged amount in the atrium. There is no choroid plexus in the anterior horn. In the third ventricle, there is a small amount in the roof that is continuous with that in the body, via the interventricular foramina, the channels that connect the lateral ventricles with the third ventricle. A choroid plexus is in part of the roof of the fourth ventricle.
In addition, aminoethoxyvinyl glycine and methoxyvinyl glycine have been shown to inhibit both shake and static cultures. Production of mycotoxins or secondary metabolites by P. digitatum has not been observed, although this species has been shown to be toxic to both shrimp and chicken embryos. With respect to fungicidal tolerance, there are known strains of P. digitatum resistant to various commonly used fungicides. Reports have been made concerning fungicides thiabendazole, benomyl, imazalil, and sodium-o-phenylphenate, as well as the fungistatic agent biphenyl, with no prior treatment required in the latter case. The mechanism of P. digitatum resistance to imazalil is suggested to lie in the over-expression of the sterol 14α-demethylase (CYP51) protein, caused by a 199 base-pair insertion into the promoter region of the CYP51 gene, and/or by duplications of the CYP51 gene.
=== Afghanistan === Prior to the takeover of the Islamic Emirate of Afghanistan in August 2021, a member of parliament (MP) was a member of the lower house of the bicameral National Assembly of Afghanistan: a member of the Wolesi Jirga (House of People) held one of the in total 250 seats in the lower house. The 102 members of the upper house Meshrano Jirga (House of Elders) were called Senators.
Sources: en.wikipedia.org
==== Vascular tissue ==== High rates of cardiovascular disease creates a high demand for grafts for vascular bypass surgery, especially small-diameter grafts which prevent occlusion. Modifying vascular tissue grafts with RGD has been shown to inhibit platelet adhesion, improve cell infiltration and enhance endothelialization. There have also been efforts to regenerate damaged heart tissues by applying cardiac patches following myocardial infarction. The addition of RGD onto a cardiac tissue scaffold has been shown to promote cell adhesion, prevent apoptosis and enhance tissue regeneration. RGD peptide has also been used to improve endothelial cell adhesion and proliferation on synthetic heart valves.
Province of German Bohemia (Provinz Deutschböhmen), the regions of northern and western Bohemia; proclaimed a constitutive state (Land) of the German-Austrian Republic with Reichenberg (Liberec) as capital, administered by a Landeshauptmann (state captain), consecutively: Rafael Pacher (1857–1936), 29 October – 6 November 1918, and Rudolf Ritter von Lodgman von Auen (1877–1962), 6 November – 16 December 1918 (the last principal city was conquered by the Czech army but he continued in exile, first at Zittau in Saxony and then in Vienna, until 24 September 1919). Province of the Sudetenland (Provinz Sudetenland), the regions of northern Moravia and Austrian Silesia; proclaimed a constituent state of the German-Austrian Republic with Troppau (Opava) as capital, governed by a Landeshauptmann: Robert Freissler (1877–1950), 30 October – 18 December 1918. This province's boundaries do not correspond to what would later be called the Sudetenland, which contained all the German-speaking parts of the Czech lands. Bohemian Forest Region (Böhmerwaldgau), the region of Bohemian Forest/South Bohemia; proclaimed a district (Kreis) of the existing Austrian Land of Upper Austria; administered by Kreishauptmann (district captain): Friedrich Wichtl (1872–1922) from 30 October 1918. German South Moravia (Deutschsüdmähren), proclaimed a District (Kreis) of the existing Austrian land Lower Austria, administered by a Kreishauptmann: Oskar Teufel (1880–1946) from 30 October 1918. The U.S.
=== Impacts of the underrepresentation of women in certain research and clinical trials === Historically, women were often excluded from clinical trials for reasons such as hormonal variability or concerns about pregnancy-related risks. This exclusion has limited understanding of how certain diseases and treatments affect women. For example, women's cardiovascular diseases—the leading cause of death among women—remain under-researched, and treatment outcomes are often less favorable for women. Other areas with gender data gaps include HIV, some cancers, and the side effects of medication. Due to underrepresentation in trials, women experience more side effects—up to twice as many as men—which has both health and financial consequences, as noted by the French Academy of Medicine in 2016. Drug efficacy may also differ by sex.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.